ArticleEuropean journal of clinical pharmacology2025
Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy.
Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-world pharmacovigilance assessment of meropenem-associated adverse events: age stratification and time-to-onset analysis using FAERS.Frontiers in medicine · 2026Article
- Physiologically based pharmacokinetic modeling and dose adjustment of imipenem in pediatric patients with renal impairment.Frontiers in cellular and infection microbiology · 2026Article
- Clozapine Drug-Drug Interactions and Individualized Dosing in Bipolar Disorder: A Model-Informed Precision Dosing Approach.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThis study aimed to characterize the pharmacokinetics (PK) of meropenem in patients with renal impairment or on continuous renal replacement therapy (CRRT), investigate the factors contributing to PK variability, and evaluate the performance of different dosing regimens to optimize the pharmacokinetics/pharmacodynamics PK/PD) targets.
methodsThis study enrolled patients with severe infections and renal impairment who received meropenem treatment at the Second Affiliated Hospital of Soochow University. Participants were grouped according to whether CRRT was used. Meropenem concentrations were quantified using liquid chromatography-tandem mass spectrometry (LC/MS-MS). A population pharmacokinetic (PPK) model for meropenem was developed using a nonlinear mixed-effects modeling (NONMEM) approach. Monte Carlo simulations were performed to evaluate the likelihood of achieving PK/PD targets and the risk of adverse events across various dosing regimens.
resultsA total of 54 patients were included in the study. A two-compartment model was used as a structural model and CRRT was identified as a significant covariate of clearance (CL). The estimated typical value of CL was 2.47 L/h. Under physiological conditions, renal impairment usually leads to a decrease in meropenem clearance. Compared with patients with renal impairment (estimated glomerular filtration rate < 45 mL/min/1.73 m
conclusionsThe study identified that CRRT significantly affected the exposure of meropenem in patients with renal impairment. Therefore, individualized medication for CRRT patients is of great importance.
Indexed as
Identifiers
40884551What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.